Management of Hypoglycaemic Episodes in Haemochromatosis
Treat hypoglycaemic episodes in haemochromatosis patients identically to standard hypoglycaemia management: administer 20g of oral glucose if the patient can swallow, or give 1mg glucagon IM/SC or 25g IV glucose if they cannot. The presence of haemochromatosis does not alter acute hypoglycaemia treatment protocols 1.
Acute Treatment Algorithm
If Patient is Conscious and Able to Swallow:
- Administer 20g of oral glucose (glucose tablets, juice, soft drinks, milk, or candy) 1
- Expect clinical improvement within 15-20 minutes
- Follow with a substantial snack or meal after initial glucose administration, as the glycemic response is transient (typically <2 hours) 1
- Monitor blood glucose serially to assess individual response
If Patient is Unconscious or Unable to Swallow:
- First-line parenteral treatment: 1mg glucagon IM or SC (can be administered by family members or caregivers) 1
- Alternative: 25g IV glucose (standard in medical settings) 1
- Be aware that glucagon may cause transient hyperglycemia, nausea, and vomiting 1
- Provide oral food as soon as the patient can safely ingest it
- Consider glucose infusion if needed, as IV glucose effects are transient 1
Critical Haemochromatosis-Specific Considerations
Understanding the Underlying Mechanism:
Haemochromatosis patients develop glucose abnormalities through impaired insulin secretion due to iron deposition in pancreatic beta cells, not primarily through insulin resistance 2, 3. This is crucial because:
- Early haemochromatosis (without cirrhosis or diabetes): Patients have decreased acute insulin response to glucose but normal insulin sensitivity 2
- With cirrhosis: Patients develop insulin resistance while maintaining relatively normal insulin secretion 2
- With established diabetes: Both insulin secretion and sensitivity are impaired 2, 3
Post-Episode Evaluation Required:
After stabilizing the acute episode, investigate the underlying cause 1:
- Review medications: Check for insulin, sulfonylureas, or other hypoglycemic agents
- Assess disease stage: Determine if cirrhosis is present (which increases hypoglycemia risk through impaired gluconeogenesis) 4
- Evaluate nutritional status: Malnutrition is common in advanced liver disease and contributes to hypoglycemia 4
- Consider alcohol use: Alcohol impairs gluconeogenesis and is particularly problematic in liver disease 1
Long-Term Prevention Strategy:
For patients with haemochromatosis and recurrent hypoglycemia, therapeutic phlebotomy is essential 5, 2:
- Phlebotomy can reverse impaired insulin secretion and normalize glucose tolerance in early haemochromatosis (before cirrhosis develops) 2
- Target ferritin: 50 μg/L during induction phase, 50-100 μg/L during maintenance 5
- However, phlebotomy does not improve glucose metabolism once cirrhosis or diabetes is established 2
Common Pitfalls to Avoid
Do not assume hyperglycemia: Haemochromatosis patients can develop hypoglycemia, especially with advanced liver disease or if overtreated with diabetes medications 6, 4
Do not delay treatment for diagnostic workup: Raise plasma glucose promptly to prevent brain injury; profound, prolonged hypoglycemia can cause permanent neurologic damage or death 1
Do not rely solely on point-of-care glucose monitors for diagnosis: Use laboratory-measured plasma glucose when possible for accurate assessment 1
Do not overlook sulfonylurea-induced hypoglycemia: These episodes can be prolonged and may require hospitalization with continuous glucose monitoring and octreotide treatment 1
Avoid post-treatment hyperglycemia after severe episodes: While glucose must be normalized promptly, excessive glucose administration may contribute to neuronal injury after profound hypoglycemia 1
Specific Monitoring for Haemochromatosis Patients
If the patient has diabetes and haemochromatosis:
- Adjust glycemic targets upward if recurrent hypoglycemia occurs 1
- Consider continuous glucose monitoring in advanced liver disease 4
- Screen for hypoglycemia unawareness: 2-3 weeks of scrupulous hypoglycemia avoidance can restore awareness 1
- Monitor for unexplained reduction in insulin or phlebotomy requirements, which may indicate alternative pathology 5